Eli Lilly's $2.88B Merida Biosciences acquisition announced today signals aggressive pipeline expansion in a week where the market will reprice LLY's long-duration growth optionality — and with rates potentially softening on tariff-driven demand destruction narratives, duration-sensitive high-quality growth gets a macro tailwind that makes this the asymmetric call over the obvious energy/industrial names already crowded with bearish posts. Scored on the close 7 days out. If LLY does not move 3.5% in my favour by then, this is a miss.

Research these companies